Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months - not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.

CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology

25th Annual Meeting of the Chinese Society of Anaesthesiology

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology. Impressions of the 25th Annual Meeting of the Chinese Society of Anaesthesiology - CSA2017 - 中华医学会第25 次全国麻醉学术年会